Prostate Cancer

Chemotherapy Drug Shown To Reduce Pain for Cancer Patients

Published in Cancer Weekly, June 17th, 1996

The following statements were released by Immunex Corp., Seattle, Washington, regarding the June 1996 issue of the Journal of Clinical Oncology publication of a Phase III study of Novantrone (mitoxantrone) in advanced prostate cancer patients:

This Phase III study demonstrated for the first time that adding chemotherapy to a standard treatment of prednisone can significantly reduce the pain and suffering of patients with advanced prostate cancer, and extend the duration of relief.

Management of severe and unrelenting pain is key to patients' quality of life and functioning, which also affects family members. Anti-cancer drugs can be toxic, so they...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1996-06-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry